Umer Sayeed-Shah

Dr. Umer Sayeed-Shah brings his expertise in finance and the capital markets, cardiovascular medicine, and bio-medical science to Flow Cell.

Dr. Shah is a leading cardiovascular surgeon and scientist. He is a graduate of Boston University School of Medicine. He completed his Residency in Cardiovascular and Thoracic Surgery at Yale University. He completed both his Research Fellowship and Clinical Fellowship in Cardiovascular Surgery at Harvard University and the Brigham and Women’s Hospital. He was trained in the laboratories and under the mentorship of Dr. Lawrence H Cohn, in the Division of Cardiac Surgery, and Dr. Victor Dzau in the Division of Cardiology and Molecular Medicine at Harvard Medical School.

Dr. Shah is a pioneer in laser-thermolysis, gene therapy, tissue engineering, and cell reprogramming. He has received international recognition through numerous awards and academic honors for his clinical and scientific expertise and for the development of novel methodologies in both minimally invasive surgery and molecular medicine. Among these are the American Association for Thoracic Surgery First Annual C. Walton Lillehei Award, the American College of Cardiology Young Investigator Award in Molecular and Cellular Cardiology, the American Heart Association Travel Fellowship, and the Medtronic Award at Harvard Medical School. He is the recipient of patents from both the United States and the European Union relating to basic and translational methodologies and applications in gene therapy, minimally-invasive surgery, and laser surgery.

Dr. Shah has previously served as an Instructor in Surgery at Yale University, Assistant Professor of Surgery at Boston University, and Director at the Harvard Center for Minimally Invasive Surgery. He is a diplomate of the American Board of Surgery, American Board of Thoracic Surgery, and of the American Heart Association Council on Cardiothoracic and Vascular Surgery.

Dr. Shah is the founder of BostonInformatix, LLC, a Cambridge - based market analytics firm, and is the inventor of the broadly referenced AI-based, algorithmic trading platform, the SuperIndexTM. He is at present a principal of Roe Capital Management, LLC, and has a keen interest in mentoring and guiding biotechnology firms.